<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14811-bib-0010">
 <label>10</label>
 <mixed-citation publication-type="journal" id="cas14811-cit-0010">
  <string-name>
   <surname>Bajetta</surname>
   <given-names>E</given-names>
  </string-name>, 
  <string-name>
   <surname>Catena</surname>
   <given-names>L</given-names>
  </string-name>, 
  <string-name>
   <surname>Procopio</surname>
   <given-names>G</given-names>
  </string-name>, et al. 
  <article-title>Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low‐grade and high‐grade neuroendocrine tumours?</article-title>
  <source xml:lang="en">Cancer Chemother Pharmacol</source>. 
  <year>2007</year>;
  <volume>59</volume>:
  <fpage>637</fpage>‐
  <lpage>642</lpage>.
  <pub-id pub-id-type="pmid">16937105</pub-id>
 </mixed-citation>
</ref>
